ValuEngine upgraded shares of Kura Oncology, Inc. (NASDAQ:KURA) from a sell rating to a hold rating in a research note released on Friday, September 8th.
Several other analysts also recently weighed in on KURA. Cann restated a buy rating and set a $16.00 target price on shares of Kura Oncology in a research note on Monday, May 15th. Zacks Investment Research upgraded Kura Oncology from a hold rating to a buy rating and set a $10.00 target price for the company in a research note on Thursday, May 18th. Oppenheimer Holdings, Inc. set a $16.00 target price on Kura Oncology and gave the company a buy rating in a research note on Wednesday, June 14th. Citigroup Inc. set a $13.00 target price on Kura Oncology and gave the company a buy rating in a research note on Tuesday, August 8th. Finally, Leerink Swann restated an outperform rating and set a $18.00 target price (up from $16.00) on shares of Kura Oncology in a research note on Thursday, August 10th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $15.60.
Shares of Kura Oncology (KURA) opened at 12.95 on Friday. The firm’s 50-day moving average price is $8.37 and its 200-day moving average price is $8.90. Kura Oncology has a one year low of $4.00 and a one year high of $13.80. The stock’s market capitalization is $258.84 million.
Kura Oncology (NASDAQ:KURA) last announced its earnings results on Monday, August 7th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.03. Equities research analysts anticipate that Kura Oncology will post ($1.53) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Kura Oncology, Inc. (KURA) Rating Increased to Hold at ValuEngine” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://ledgergazette.com/2017/09/17/kura-oncology-inc-kura-stock-rating-upgraded-by-valuengine.html.
A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Kura Oncology by 13.0% in the second quarter. Vanguard Group Inc. now owns 433,868 shares of the company’s stock worth $4,035,000 after purchasing an additional 50,033 shares in the last quarter. Morgan Stanley grew its stake in Kura Oncology by 175.5% in the first quarter. Morgan Stanley now owns 430,428 shares of the company’s stock worth $3,788,000 after purchasing an additional 274,166 shares in the last quarter. Alethea Capital Management LLC grew its stake in Kura Oncology by 128.1% in the second quarter. Alethea Capital Management LLC now owns 193,346 shares of the company’s stock worth $1,798,000 after purchasing an additional 108,577 shares in the last quarter. State Street Corp acquired a new position in Kura Oncology in the second quarter worth about $1,394,000. Finally, Northern Trust Corp grew its stake in Kura Oncology by 939.3% in the second quarter. Northern Trust Corp now owns 147,483 shares of the company’s stock worth $1,372,000 after purchasing an additional 133,293 shares in the last quarter. Institutional investors and hedge funds own 39.07% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.